Arcturus Therapeutics Holdings Inc ARCT.OQ ARCT.O is expected to show a fall in quarterly revenue when it reports results on November 10 for the period ending September 30 2025
The San Diego California-based company is expected to report a 49.1% decrease in revenue to $21.196 million from $41.67 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Arcturus Therapeutics Holdings Inc is for a loss of 82 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $23.00, about 62.1% above its last closing price of $8.72
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.78 | -0.89 | -0.34 | Beat | 61.9 |
Mar. 31 2025 | -1.26 | -1.33 | -0.52 | Beat | 60.9 |
Dec. 31 2024 | -0.52 | -0.55 | -1.11 | Missed | -102.2 |
Sep. 30 2024 | -1.23 | -1.22 | -0.26 | Beat | 78.6 |
Jun. 30 2024 | -1.51 | -1.60 | -0.64 | Beat | 60 |
Mar. 31 2024 | -1.21 | -1.19 | -1.00 | Beat | 15.9 |
Dec. 31 2023 | -0.60 | -0.99 | -0.32 | Beat | 67.7 |
Sep. 30 2023 | -1.72 | -1.69 | -0.61 | Beat | 63.9 |
This summary was machine generated November 7 at 23:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments